Physician profile
Jeffrey Jacobs
NPI 1992143705
$13,171.93
in general payments reported to CMS, 2019-2025
7 companies · $2,555 in 2025
The $2,555 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $81.66 · 2021: $403 · 2022: $7,684 · 2023: $2,232 · 2024: $71.51 · 2025: $2,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,100 · Consulting Fee: $1,815 · Food and Beverage: $918 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,100.00 |
| Consulting Fee | $1,815.00 |
| Food and Beverage | $917.58 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $7,728.58 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,261.49 | 2022-2025 | Entyvio |
| Celgene Corporation | $1,734.62 | 2021-2023 | Zeposia |
| Abbvie INC. | $1,056.87 | 2021-2025 | |
| Janssen Biotech, INC. | $309.31 | 2019-2025 | Tremfya |
| Olympus America INC. | $55.36 | 2019 | |
| Merck Sharp & Dohme LLC | $25.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.